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ABSTRACT Carbapenem-resistant Pseudomonas aeruginosa is defined as a “critical” pri-
ority pathogen for the development of new antibiotics. Here we report the complete
genome sequence of an extensively drug-resistant, Verona integron-encoded metallo--
lactamase-expressing isolate belonging to the high-risk sequence type 233.
Carbapenem-resistant Pseudomonas aeruginosa is a critical threat to public health(1). P. aeruginosa K34-7 belongs to sequence type 233 (ST233) and is an extensively
drug-resistant (XDR), carbapenem-resistant clinical isolate expressing the Verona
integron-encoded metallo--lactamase (VIM-2) (2). ST233 has been identified as a
high-risk clone in both Mexico (3) and the United States (4). K34-7 was the first
metallo--lactamase-producing P. aeruginosa isolate identified in Norway, and PCR
analysis previously confirmed that the blaVIM-2 gene was contained within an unusual
class 1 integron (GenBank accession number FM165436) (2). As only one other P.
aeruginosa ST233 complete genome has been published (5), this high-quality P. aerugi-
nosa K34-7 genome will provide a valuable additional genomic resource for investiga-
tion of this high-risk ST.
Genomic DNA was prepared from a culture grown from a single colony using the Mo
Bio DNeasy UltraClean microbial kit (Qiagen, USA) and sequenced on a PacBio RS II
platform. A standard library of 20-kb fragments was prepared using the BluePippin
preparative electrophoresis system (Sage Science, USA) with a 9-kb cutoff and se-
quenced on a single-molecule real-time (SMRT) cell using P6-C4 chemistry with 360-min
movie-time chemistry. Additional whole-genome sequencing (WGS) was performed
using an Illumina HiSeq sequencer. Genome assembly involved a de novo approach,
using default HGAP 4 settings for the assembly of 96,269 PacBio reads (average length,
10,760 bp), before manual curation and validation. Iterative read mapping of Illumina
sequences using custom settings in Geneious 10.1.3 (6) was used to identify assembly
errors, primarily single-base insertions and deletions, and for variant correction (0.7
minimum variant frequency, 5 minimum coverage). Custom settings included al-
lowed gaps (15% maximum/read and 15-bp maximum size); word and index word
lengths of 18 and 13, respectively; and 20% maximum mismatch/read and maximum
ambiguity of 4.
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The K34-7 genome consists of a 7,038,012-bp chromosome and one plasmid,
pK34-7-1 (4,440 bp). A P. aeruginosa genomic island 5 (PAGI-5)-like hybrid (7) patho-
genicity island (84,893 bp) and bacteriophage (38,832 bp) were found on the chromo-
some (positions 4154015 to 4238618 and 6469185 to 6508016, respectively). The XDR
K34-7 phenotype is predominantly due to genes associated with three chromosomally
located class 1 integrons, including genes imparting resistance to aminoglycosides
[aac(3), aac(3)-I, aac(6´)-Il, aadA2, and aph(3´)-IIb], -lactams (blaOXA-4, blaOXA-486,
blaPDC-3, and blaVIM-2), chloramphenicol (catB, cmlA6, and floR), trimethoprim (dfrB5),
fosfomycin (fosA), sulfonamide (sul1), and tetracycline (tetG), as annotated by the PGAP
pipeline (8). Additionally, tetK, encoding the tetracycline efflux pump TetK, is found on
the small pK34-7-1 plasmid.
A region (1936000 to 2043700) of 12 direct tandem repeats (7,122 bp, 11.5 mean
Illumina coverage) encodes a zonular occludens toxin, previously characterized in Vibrio
cholerae (9, 10). Similar regions appear in other P. aeruginosa genomes but not in the
ST233 P. aeruginosa PA83 genome (5). Additionally, P. aeruginosa K34-7 contains a type
I-F CRISPR-Cas system (1656563 to 1664702), previously described in P. aeruginosa
strain UCBPP-PA14 (11).
Complete high-quality bacterial genomes facilitate further research into mecha-
nisms of resistance and their dissemination and aid in the development of new
therapies for XDR infections.
Data availability. This complete genome project has been deposited at GenBank
under the accession numbers CP029707 and CP029708.
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